1-3 of 3
Michael Weickert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Zelenirstat Nmt Inhibitor in Patients with Relapsed/Refractory B-Cell Lymphoma and Acute Myelogenous Leukemia: Mechanistic Insights and Clinical Outcomes

Randeep Sangha, John Kuruvilla, Laurie H. Sehn, Michael Weickert, Erwan Beauchamp, Jay M. Gamma, Naveen Pemmaraju, Gautam Borthakur, Luc G. Berthiaume, John R. Mackey
Journal: Blood
Blood (2024) 144 (Supplement 1): 5791.
https://doi.org/10.1182/blood-2024-208480
Published: 2024
Journal Articles

A First-in-Human, Open-Label, Phase I Dose Escalation Trial of Daily Oral Nmt Inhibitor Zelenirstat in Patients with Relapsed/Refractory B-Cell Lymphomas and Advanced Solid Tumors

Randeep Sangha, Rahima Jamal, Jennifer Spratlin, John Kuruvilla, Laurie H. Sehn, Michael Weickert, Luc Berthiaume, John Robert Mackey
Journal: Blood
Blood (2023) 142 (Supplement 1): 6241.
https://doi.org/10.1182/blood-2023-190058
Published: 2023
Journal Articles

Initial Characterization and Toxicology of an Nmt Inhibitor in Development for Hematologic Malignancies

Michael Weickert, John Dillberger, John R. Mackey, Paul Wyatt, David Gray, Kevin Read, Christian Li, Audrey Parenteau, Luc G. Berthiaume
Journal: Blood
Blood (2019) 134 (Supplement_1): 3362.
https://doi.org/10.1182/blood-2019-124934
Published: 2019